Abstract
Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20(+), ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab's potential in MRD(+) Ph-negative B-ALL CD20(+), warranting further clinical investigation.